noodls browser compatibility check

The security settings of your browser are blocking the execution of scripts.

To use noodls, javascript support must be enabled. Please change your browser's security settings to enable javascript.

If you have changed your browser's security settings, you can click here.

related announcements

News

Texas Workforce Commission

Texas Adds 17,600 Jobs as Labor Force Grows in August
The Office of the Governor of the[...]

Sanders Signs Certification of Vacancy
The Office of the Governor of the[...]

Sanders Negotiates Insurance Rate Increases Down by 35.8%

Healthcare

Prelude Therapeutics Inc.

09/19/2025 | Press release | Distributed by Public on 09/19/2025 05:41

Material Event (Form 8-K)

Item 8.01 Other Events

As previously disclosed on March 28, 2025, Prelude Therapeutics Incorporated (the "Company") received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") on March 27, 2025, notifying the Company that it was not in compliance with the Nasdaq Minimum Bid Price Requirement because its common stock, par value $0.0001 per share (the "Common Stock") had failed to meet the $1.00 per share Minimum Bid Price Requirement.

On September 18, 2025, the Company received a letter from Nasdaq notifying the Company that it has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) (the "Minimum Bid Price Requirement") and that the matter is now closed.

Prelude Therapeutics Inc. published this content on September 19, 2025, and is solely responsible for the information contained herein. Distributed via SEC EDGAR on September 19, 2025 at 11:42 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]